Switch to biologic for RA more about prescribers than patients

Researchers examined factors associated with the length of time from first conventional synthetic disease-modifying antirheumatic drug to receipt of first biologic in a retrospective cohort study using administrative data for patients with identical single-payer health insurance coverage in Ontario.

Read the full article here

Related Articles